Researchers at the University of Eastern Finland have identified the SMVT transporter protein that can improve creatine delivery to the brain and potentially enable new therapies targeting the central nervous system. The discovery addresses one of medicine's greatest challenges: delivering drugs across the blood-brain barrier.
Otsuka Pharmaceutical and Ionis Pharmaceuticals announced their experimental drug ulefnersen met the main goal of a late-stage study in patients with a rare inherited form of amyotrophic lateral sclerosis (ALS), showing improvements in functional impairment and survival. The partners plan to approach the FDA to determine potential regulatory pathways.
Jazz Pharmaceuticals announced a definitive agreement to acquire privately-held Actio Biosciences for $820 million upfront plus up to $500 million in milestone payments, gaining access to ABS-1230, an experimental treatment for KCNT1+ epilepsy, a rare inherited form of the disease with no approved therapies.